Sitaxsentan sodium appears to be more cost effective than bosentan in treating patients with pulmonary arterial hypertension (PAH)

Author：  

Publisher： Adis International

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.508, 2006-01, pp. : 7-7

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Inhaled treprostinil is an effective, well-tolerated add-on therapy for patients with pulmonary arterial hypertension (PAH) treated with bosentan

By  

Inpharma, Vol. 1, Iss. 1561, 2006-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Bosentan: In Pediatric Patients with Pulmonary Arterial Hypertension

By Carter Natalie J.   Keating Gillian M.  

Pediatric Drugs, Vol. 12, Iss. 1, 2010-02 ,pp. : 63-73

Adis International

Access to resources Recommend Favorite

Bosentan potentially cost effective in PAH

By  

Inpharma, Vol. 1, Iss. 1556, 2006-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Bosentan potentially cost effective in PAH

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 512, 2006-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Sitaxsentan STRIDEs ahead in pulmonary arterial hypertension

By  

Inpharma, Vol. 1, Iss. 1494, 2005-01 ,pp. : 7-8

Adis International

Access to resources Recommend Favorite